Brokerages Set Prestige Consumer Healthcare Inc. (NYSE:PBH) Target Price at $85.25

Prestige Consumer Healthcare Inc. (NYSE:PBH) has received an average rating of “Moderate Buy” from the four research firms that are currently covering the company, Marketbeat.com reports. Two equities research analysts have rated the stock with a hold rating and two have issued a buy rating on the company. The average 12 month price target among brokers that have covered the stock in the last year is $85.25.

A number of brokerages recently weighed in on PBH. Raymond James raised shares of Prestige Consumer Healthcare to a “moderate buy” rating in a research report on Thursday, December 19th. Jefferies Financial Group reissued a “hold” rating and issued a $76.00 target price (up from $70.00) on shares of Prestige Consumer Healthcare in a report on Tuesday, September 24th. StockNews.com downgraded Prestige Consumer Healthcare from a “buy” rating to a “hold” rating in a research note on Monday, December 30th. Sidoti cut Prestige Consumer Healthcare from a “buy” rating to a “neutral” rating and set a $90.00 price objective for the company. in a research note on Monday, December 9th. Finally, DA Davidson restated a “buy” rating and set a $95.00 target price on shares of Prestige Consumer Healthcare in a research report on Monday, November 11th.

Insider Buying and Selling at Prestige Consumer Healthcare

In other news, insider William P’pool sold 8,987 shares of the firm’s stock in a transaction on Tuesday, November 12th. The shares were sold at an average price of $81.85, for a total value of $735,585.95. Following the completion of the sale, the insider now owns 20,058 shares in the company, valued at approximately $1,641,747.30. This trade represents a 30.94 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, EVP Adel Mekhail sold 9,063 shares of the business’s stock in a transaction dated Tuesday, November 12th. The stock was sold at an average price of $82.00, for a total transaction of $743,166.00. Following the transaction, the executive vice president now owns 18,365 shares in the company, valued at approximately $1,505,930. This trade represents a 33.04 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 38,810 shares of company stock worth $3,187,300. 1.60% of the stock is currently owned by insiders.

Institutional Trading of Prestige Consumer Healthcare

Several hedge funds have recently modified their holdings of PBH. Victory Capital Management Inc. raised its position in Prestige Consumer Healthcare by 9.0% in the second quarter. Victory Capital Management Inc. now owns 2,074,460 shares of the company’s stock worth $142,827,000 after acquiring an additional 171,357 shares in the last quarter. Arizona State Retirement System lifted its stake in shares of Prestige Consumer Healthcare by 1.9% in the second quarter. Arizona State Retirement System now owns 13,900 shares of the company’s stock valued at $957,000 after purchasing an additional 264 shares during the period. Norden Group LLC boosted its holdings in Prestige Consumer Healthcare by 25.9% during the second quarter. Norden Group LLC now owns 12,435 shares of the company’s stock worth $856,000 after buying an additional 2,559 shares in the last quarter. Quest Partners LLC grew its position in Prestige Consumer Healthcare by 2,826.7% during the second quarter. Quest Partners LLC now owns 439 shares of the company’s stock worth $30,000 after buying an additional 424 shares during the period. Finally, Choreo LLC acquired a new position in Prestige Consumer Healthcare during the second quarter worth about $677,000. 99.95% of the stock is owned by institutional investors and hedge funds.

Prestige Consumer Healthcare Trading Down 1.1 %

NYSE:PBH opened at $76.88 on Friday. Prestige Consumer Healthcare has a 1 year low of $57.95 and a 1 year high of $86.36. The stock has a market cap of $3.80 billion, a P/E ratio of 18.71, a P/E/G ratio of 2.32 and a beta of 0.51. The company has a debt-to-equity ratio of 0.61, a quick ratio of 2.10 and a current ratio of 3.56. The stock has a 50-day simple moving average of $80.50 and a 200-day simple moving average of $74.01.

Prestige Consumer Healthcare (NYSE:PBH) last posted its earnings results on Thursday, November 7th. The company reported $1.09 earnings per share for the quarter, hitting the consensus estimate of $1.09. Prestige Consumer Healthcare had a return on equity of 12.23% and a net margin of 18.54%. The firm had revenue of $283.79 million during the quarter, compared to analysts’ expectations of $282.09 million. During the same quarter in the previous year, the business earned $1.07 earnings per share. The firm’s revenue was down .9% compared to the same quarter last year. As a group, analysts anticipate that Prestige Consumer Healthcare will post 4.44 earnings per share for the current fiscal year.

Prestige Consumer Healthcare Company Profile

Prestige Consumer Healthcare Inc, together with its subsidiaries, develops, manufactures, markets, distributes, and sells over-the-counter (OTC) health and personal care products in the United States and internationally. The company operates in two segments, North American OTC Healthcare and International OTC Healthcare.